Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20623016 | 0.86 | TACR1 (0.33) | TACR1TACR3ECE1CCKBR | |
| SCHEMBL19756282 | 0.84 | GRIA1 (0.44) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL19756279 | 0.83 | KDM4E (0.34) | ECE1CCKBR | |
| SCHEMBL21536833 | 0.80 | GRIA1 (0.37) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL18477469 | 0.77 | HPGD (0.35) | — | |
| SCHEMBL24823972 | 0.75 | TACR1 (0.32) | TACR1TACR3 | |
| SCHEMBL21285412 | 0.73 | KDM4E (0.33) | — | |
| SCHEMBL19756283 | 0.72 | — | — | |
| SCHEMBL19756277 | 0.72 | DPP7 (0.36) | TACR1TACR3ECE1 | |
| SCHEMBL1963990 | 0.72 | HPGD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-12-29 | — | — | US | disclosed |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-11154593-B2 | CNP prodrugs with large carrier moieties | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-10-26 | — | — | US | disclosed |
| US-20210177942-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-06-17 | — | — | US | disclosed |
| US-20210077584-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2021-03-18 | — | — | US | disclosed |
| US-20210069339-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| US-10835578-B2 | CNP prodrugs with large carrier moieties | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-11-17 | — | — | US | disclosed |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-09-03 | — | — | US | disclosed |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190328841-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190255183-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-03 | — | — | US | disclosed |
| US-20170368189-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | GRIA1 639/4885TACR1 99/4885TACR3 151/4885 |
| US-11154593-B2 | CNP prodrugs with large carrier moieties | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20210069339-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | GRIA1 3408/4885TACR1 64/4885TACR3 166/4885 |
| US-20190255183-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | GRIA1 3408/4885TACR1 64/4885TACR3 166/4885 |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | NPR1, NPR3, CNP | GRIA1 723/4885TACR1 131/4885TACR3 81/4885 |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | GRIA1 778/4885TACR1 137/4885TACR3 310/4885 |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | GRIA1 567/4885TACR1 24/4885TACR3 53/4885 |
| US-20210077584-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | GRIA1 567/4885TACR1 24/4885TACR3 53/4885 |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | NPR1, NPR3, NPSR1 | GRIA1 567/4885TACR1 24/4885TACR3 53/4885 |
| US-20190328841-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | GRIA1 639/4885TACR1 99/4885TACR3 151/4885 |
| US-20210177942-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | GRIA1 778/4885TACR1 137/4885TACR3 310/4885 |
| US-10835578-B2 | CNP prodrugs with large carrier moieties | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20170368189-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | GRIA1 3408/4885TACR1 64/4885TACR3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.